Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $87.3 million.

  • Kymera Therapeutics' Shares Outstanding (Diluted Average) rose 14.68% to $87.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.3 million, marking a year-over-year increase of 14.68%. This contributed to the annual value of $75.0 million for FY2024, which is 28.58% up from last year.
  • Latest data reveals that Kymera Therapeutics reported Shares Outstanding (Diluted Average) of $87.3 million as of Q3 2025, which was up 8.52% from $80.4 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Shares Outstanding (Diluted Average) peaked at $87.3 million during Q3 2025, and registered a low of $45.1 million during Q2 2021.
  • For the 3-year period, Kymera Therapeutics' Shares Outstanding (Diluted Average) averaged around $70.6 million, with its median value being $73.1 million (2024).
  • Data for Kymera Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY surged of 176.60% (in 2021) over the last 5 years.
  • Kymera Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $48.0 million in 2021, then rose by 12.39% to $53.9 million in 2022, then rose by 8.22% to $58.4 million in 2023, then rose by 28.58% to $75.0 million in 2024, then increased by 14.68% to $87.3 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $87.3 million in Q3 2025, compared to $80.4 million in Q2 2025 and $80.1 million in Q1 2025.